PFSCF - Prometic Life Sciences Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0180
-0.0010 (-5.26%)
At close: 3:57PM EDT
Stock chart is not supported by your current browser
Previous Close0.0190
Open0.0175
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0152 - 0.0180
52 Week Range0.0150 - 0.7500
Volume241,578
Avg. Volume210,471
Market Cap412.054M
Beta (3Y Monthly)2.78
PE Ratio (TTM)N/A
EPS (TTM)-0.1380
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • CNW Group6 days ago

    Prometic Announces Voting Results of its 2019 AGM

    Prometic Announces Voting Results of its 2019 AGM

  • CNW Group8 days ago

    Prometic announces completion of equity rights offering

    LAVAL, QC , ROCKVILLE , MD  and CAMBRIDGE, United Kingdom , June 17, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") is pleased to confirm the completion of its previously announced equity rights offering, raising aggregate gross proceeds of C$37,998,000 (or the equivalent of US$ 28,357,000 ) (the "Rights Offering"). Following the Rights Offering, 23,218,813,405 common shares of the Corporation are issued and outstanding.

  • PR Newswire11 days ago

    Prometic Presents New Data on PBI-4050 and its Mechanism of Action on Kidney Fibrosis at the 56th ERA/EDTA Congress

    LAVAL, QC , ROCKVILLE , MD and CAMBRIDGE, United Kingdom , June 14, 2019 /PRNewswire/ -  Prometic Life Sciences Inc.  (TSX: PLI) (OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused on developing ...

  • PR Newswire26 days ago

    Prometic Life Sciences to Present at Two Upcoming June Investor Conferences

    LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, May 30, 2019 /PRNewswire/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) (Prometic), a biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today announced that members of the management team will provide a business overview and update at the 2019 Jeffries Global Healthcare Conference at 14:30 EDT on Thursday, June 6, 2019 and at the Raymond James Life Sciences & MedTech Conference at 15:35 EDT on Wednesday, June 19, both in New York, NY. Prometic (www.prometic.com) is an innovative biopharmaceutical corporation with a broad pipeline of small molecule therapeutics under development to treat unmet needs in patients with liver, respiratory and kidney disease, including rare diseases.

  • CNW Grouplast month

    Prometic presents new PBI-4050 and Ryplazim™ (plasminogen) data on lung fibrosis at the 2019 ATS Conference

    LAVAL, QC and CAMBRIDGE, United Kingdom , May 22, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) (Prometic) today announced the presentation of three scientific posters on the Company's lead small molecule and plasma-derived drug product candidates, respectively PBI-4050 and Ryplazim™ (plasminogen), on lung fibrosis indications, at the American Thoracic Society (ATS) 2019 International Conference taking place in Dallas, Texas , from May 17 – 22, 2019. "These pre-clinical results provide additional evidence demonstrating the anti-fibrotic activity of PBI-4050, and its potential as a novel therapy for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Importantly, PBI-4050 has now been demonstrated to reduce fibrosis in two models of pulmonary fibrosis, commented Dr. Lyne Gagnon, Vice President of Preclinical R&D at Prometic.

  • CNW Grouplast month

    Prometic announces terms of equity rights offering

    LAVAL, QC , May 15, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic" or the "Corporation") is pleased to confirm the terms of its previously announced equity rights offering for gross proceeds of up to $75,000,000 (the "Rights Offering"). The Corporation will be offering rights to the holders of record of its outstanding common shares (the "Common Shares") at the close of business on May 21, 2019 (the "Record Date"), on the basis of one right for each Common Share held, on the terms summarized hereafter and more fully detailed in the Corporation's rights offering circular which will be available under Prometic's profile at www.sedar.com (the "Rights Offering Circular"). Each right will entitle the holder to subscribe for up to twenty (20) Common Shares upon payment of a subscription price rounded to the nearest 5 decimals of $0.01521 per Common Share, subject to proration as described below.

  • CNW Group2 months ago

    Prometic reports its 2019 first quarter financial results

    LAVAL, QC , May 8, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic" or the "Corporation") reported today its unaudited financial results for the first quarter ended March 31, 2019 . "We are pleased to have completed the recapitalization transactions and equity offering in April that have provided both an improved capital structure and necessary cash liquidity from the $ 75 million  gross proceeds received from Structured Alpha LP and Consonance Capital Management", stated Mr. Kenneth Galbraith , Chief Executive Officer. "We made excellent progress during the quarter towards completing the necessary development work to permit re-filing of our Ryplazim™ (plasminogen) ("RyplazimTM ") BLA before the end of 2019.

  • PR Newswire2 months ago

    Prometic strengthens its leadership with a new management structure and the appointment of three new directors

    LAVAL, QC and CAMBRIDGE, United Kingdom, May 8, 2019 /PRNewswire/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic" or "Corporation") is pleased to announce today a new management structure to provide leadership to the Corporation  and the appointment of Dr. Gary Bridger, Mr. Timothy Wach and Mr. Neil Klompas to the Board of Directors. All three of these individuals will be included as nominees for election to the Board of Directors by shareholders at the upcoming Annual General and Special Meeting of the shareholders ("AGM") scheduled to take place in Montreal, Québec, Canada on June 19, 2019. Also, Mr. Bruce Wendel, Chief Business Development Officer, has left the Corporation.

  • CNW Group2 months ago

    Prometic Completes Refinancing Transactions Including C$75 Million (approximately US$56 Million) in Gross Proceeds from New Equity Financing

    LAVAL, QC , April 23, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic" or the "Corporation") is pleased to announce today's closing of the recapitalization and equity offering previously announced on April 15, 2019 . Prometic received C$75 million (approximately US$56 million ) in gross proceeds from the equity offering led by Consonance Capital Management ("Consonance") and Structured Alpha LP ("SALP") and converted into equity substantially all of its indebtedness to SALP. Prometic is also pleased to announce the appointment of Stefan Clulow , Managing Director and Chief Investment Officer of Thomvest Asset Management, as Chair of Prometic's Board of Directors and Kenneth Galbraith as Chief Executive Officer.  Concurrent with these leadership changes, Professor Simon Best has been appointed Prometic's Lead Independent Director, and Dr. Benny Soffer , of Consonance, has been designated as a Prometic board observer.

  • CNW Group2 months ago

    Prometic Announces Refinancing Transactions

    LAVAL, QC , April 15, 2019  /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic" or the "Corporation") announced today its intention to enter into a series of related arrangements to restructure Prometic's outstanding indebtedness, reduce its interest and certain other payment obligations, and raise sufficient cash to build a robust balance-sheet for the next phase of Prometic's development. "These transactions will strengthen our balance sheet, allowing Prometic to bring its first products to market and advance its very promising small-molecule pipeline," said Professor Simon Best , Chairman and Interim CEO.

  • PR Newswire3 months ago

    Prometic reports fourth quarter and 2018 year-end financial results

    LAVAL, QC, April 1, 2019 /PRNewswire/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) (Prometic or the Corporation) reported today its financial results for the fourth quarter and year-ended December 31, 2018. Total revenues for the year ended December 31, 2018 were $47.4 million compared to $39.1 million during the comparative period of 2017, which represents an increase of $8.3 million. Total revenues for the quarter ended December 31, 2018 were $10.6 million compared to $6.6 million during the comparative period of 2017, representing an increase of $4.0 million.

  • CNW Group3 months ago

    Prometic to Report its Fourth Quarter and 2018 Year-End Financial Results and Hold Conference Call / Webcast

    LAVAL, QC , March 26, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic" or the "Corporation") announced today that it  will report its financial results for the fourth quarter and year ended December 31, 2018 on Monday April 1, 2019 after market close. Prometic (www.prometic.com) is a biopharmaceutical corporation with two drug discovery platforms focusing on unmet medical needs. The first platform (small molecule therapeutics) stems from the discovery of two receptors which we believe are at the core of how the body heals: namely, promoting tissue regeneration and scar resolution as opposed to fibrosis.

  • PR Newswire3 months ago

    Prometic secures additional USD $5 million (CAD $6.7 million) tranche from structured Alpha LP, an affiliate of Thomvest Asset Management Inc., under its existing credit facilities

    LAVAL, QC, March 25, 2019 /PRNewswire/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic" or the "Corporation") announced today that it has secured an additional USD $5 million (CAD $6.7 million) tranche from Structured Alpha LP ("SALP"), an affiliate of Thomvest Asset Management Inc., under the existing loan agreement originally entered into with SALP in November 2017. The proceeds of this loan extension will be used to satisfy the near-term cash requirements of the Corporation.

  • CNW Group4 months ago

    Prometic secures additional USD $10 million (CAD $13.2 million) tranche from Structured Alpha LP, an affiliate of Thomvest Asset Management Inc., under its existing credit facilities

    LAVAL, QC , Feb. 25, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic" or the "Corporation") announced today that it has secured an additional USD $10 million (CAD $13.2 million ) tranche from Structured Alpha LP ("SALP"), an affiliate of Thomvest Asset Management Inc., under the existing loan agreement originally entered into with SALP in November 2017 . Other than the extension of this additional tranche, the provisions of the existing credit facilities with SALP remain in full force and effect.

  • CNW Group4 months ago

    Prometic retains investment bank for strategic transactions

    LAVAL, QC , Feb. 14, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO), (PFSCF) ("Prometic" or the "Corporation") today announced that it has engaged Lazard to review and execute key strategic transactions for the Corporation focused on maximizing shareholder value. Commenting on the proposed transactions, Simon Best , Prometic's Chairman and Chief Executive Officer stated, "We have received significant interest in some of our assets to the point that it is appropriate to utilize the expertise of an experienced deal-making bank to execute these potential transactions.  While we conduct this review, we will remain focused on delivering our business plan".

  • CNW Group6 months ago

    Prof. Simon Best Appointed Interim CEO of Prometic Life Sciences

    LAVAL, QC , Dec. 19, 2018 /CNW/ - The Board of Directors of Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic" or the "Corporation")  announced today that it has named Prof. Simon Best as Interim Chief Executive Officer, effective immediately. Prof. Best has been the Chairman of the Prometic Board of Directors since May 2014 and has over 30 years of global life sciences expertise with a focus on business development, strategic planning and product commercialization.